Abstract
The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.
Keywords
BlockadeImmune checkpointCancer therapyImmune systemCancerCancer researchImmunologyMedicineComputational biologyBiologyImmunotherapyReceptorInternal medicine
MeSH Terms
AntibodiesMonoclonalAntineoplastic AgentsCD28 AntigensCTLA-4 AntigenHumansImmunotherapyModelsImmunologicalNeoplasmsProgrammed Cell Death 1 Receptor
Affiliated Institutions
Related Publications
Immune checkpoint signaling and cancer immunotherapy
Abstract Immune checkpoint blockade therapy has become a major weapon in fighting cancer. Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such a...
Coinhibitory Pathways in Immunotherapy for Cancer
The immune system is capable of recognizing tumors and eliminates many early malignant cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is im...
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
The immune system influences the fate of developing cancers by not only functioning as a tumour promoter that facilitates cellular transformation, promotes tumour growth and scu...
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequen...
Immune checkpoint inhibitors: recent progress and potential biomarkers
Cancer growth and progression are associated with immune suppression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressiv...
Publication Info
- Year
- 2015
- Type
- review
- Volume
- 27
- Issue
- 4
- Pages
- 450-461
- Citations
- 4090
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
4090
OpenAlex
113
Influential
3561
CrossRef
Cite This
Suzanne L. Topalian,
Charles G. Drake,
Drew M. Pardoll
(2015).
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy.
Cancer Cell
, 27
(4)
, 450-461.
https://doi.org/10.1016/j.ccell.2015.03.001
Identifiers
- DOI
- 10.1016/j.ccell.2015.03.001
- PMID
- 25858804
- PMCID
- PMC4400238